In accordance with these findings, a study conducted by Eroglu and colleagues revealed that out of the 14 enrolled pediatric FMF patients, three had to switch to anti-IL-1 therapy due to inadequate response and side effects (111). The gene discussed is IL1B; the disease is familial Mediterranean fever.